Golimumab for colitis, ulcerative

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Feb 2022: Trial registered, NCT05242484
  2. 19 Sep 2022: Trial started, NCT05242484

The trials

NCT05242484: A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

State
Under way
Phase
Phase 2
People
577 taking part
Started
19 Sep 2022
Primary completion
15 May 2025
Arms
Group 3: Golimumab
Results
None posted
  1. 16 Feb 2022: Trial registered
  2. 19 Sep 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Simponi.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.